Grainne O'Kane· @graokane · X·· 2 days agoScore70
Body · original
OPTIMUM rand ph2 adv #BTC
➡️dx control on plat- olaparib v olaparib/durva
➡️somatic/ germline DDR but wide range genes
➡️❗️BRCA1/2/PALB2 ~30% (⬆️Olap arm)
❎no diff 6mth PFS
❎1yr OS rate 64 v76%
❗️we must define true HRD in trials & understand TME
@myESMO #ESMO26 @OncoAlert
60 views · 1 like · 1 repost · 0 replies
Conference abstracts
LBA37matched by Proffered paper: Gynaecological cancers
Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgSource: Grainne O'Kane · x.com